Skip to content
Bored Studies
RecruitingPhase 3

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

Pfizer · NCT06641466

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–45 · Women only
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
723
US sites recruiting
32
Study start
March 11, 2025
Record last updated
July 9, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstrual period (PMP) for intermittent prevention of migraine in women who experience menstrual migraine attacks.

Being studied: Rimegepant; Placebo Comparator; Standard of Care; Rimegepant

Conditions: Menstrual Migraine

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Participant has regular menstrual cycles ≥24 days and ≤34 days
  • A minimum 1-year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition
  • A history of menstrual migraine attacks of at least 3 months
  • Participant reported history of experiencing at least 1 migraine attack during the perimenstrual period in at least 2 out of 3 menstrual cycles immediately prior to screening.
  • If the participant is receiving a permitted background continuous prophylactic migraine medication, the medication dose must be stable for at least 3 months prior to the Screening visit and, the dose is not expected to change during the course of the study

Exclusion Criteria

  • Greater than 6 migraine days per month that are outside of the perimenstrual period in the 3 months prior to Screening
  • A diagnosis of chronic migraine or a history of more than 14 headache days per month on average, in the 3 months prior to Screening
  • History of retinal migraine, basilar migraine or hemiplegic migraine
  • Current diagnosis of schizophrenia, bipolar, or borderline personality disorder
  • Other pain syndromes (eg, fibromyalgia, complex regional pain syndrome), or significant neurological disorders (other than migraine), or other medical conditions (including endocrine and gynecological eg, severe dysmenorrhea

Recruiting US locations

Study contacts (from the official record)

  • Pfizer CT.gov Call Center · 1-800-718-1021 · ClinicalTrials.gov_Inquiries@pfizer.com
All neurology studies in Arizona →
A Study to Learn About the Study Medicine Called Rimegepant in… (NCT06641466) | Bored Studies